Stock Detail
SOMAXON PHARMACEUTICALS INC
Drug Manufacturers Other
SOMX @ Yahoo Finance | SOMX Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $0.84 | $0.87 | $-0.03 | -3.45% | 0.00 | $0.87 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $0.84 | $0.84 | 63,636 | 40.31M | 235,899 | -0.56 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 0.88 | 0.86 | 0.85 | 0.83 | 0.82 |
Stock Profile
Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the in-licensing, development, and commercialization of product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology in the United States. The company's lead product includes SILENOR, for the treatment of insomnia that has completed Phase III clinical program. Its other products include Nalmefene, which would be used for smoking cessation and is in Phase II clinical trials; and for the treatment of pathological gambling and is in Phase II/III clinical trials. The company is also developing a new formulation of Acamprosate Calcium for the treatment of certain movement disorders. Somaxon Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Diego, California.